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Abstract
Background: Glucocorticoid has an important effect on lipid metabolism in muscles, and the type of fatty acid likely affects
mitochondrial utilization. Therefore, we hypothesize that the different fatty acid types treatment may affect the
glucocorticoid induction of intramuscular lipid accumulation.
Methodology/Principal Findings: The effect of dexamethasone (DEX) on fatty acid metabolism and storage in skeletal
muscle of broiler chickens (Gallus gallus domesticus) was investigated with and without fatty acid treatments. Male Arbor
Acres chickens (31 d old) were treated with either palmitic acid (PA) or oleic acid (OA) for 7 days, followed by DEX
administration for 3 days (35–37 d old). The DEX-induced lipid uptake and oxidation imbalance, which was estimated by
increased fatty acid transport protein 1 (FATP1) expression and decreased carnitine palmitoyl transferase 1 activity,
contributed to skeletal muscle lipid accumulation. More sensitive than glycolytic muscle, the oxidative muscle in DEX-
treated chickens showed a decrease in the AMP to ATP ratio, a decrease in AMP-activated protein kinase (AMPK) alpha
phosphorylation and its activity, as well as an increase in the phosphorylation of mammalian target of rapamycin (mTOR)
and ribosomal p70S6 kinase, without Akt activation. DEX-stimulated lipid deposition was augmented by PA, but alleviated
by OA, in response to pathways that were regulated differently, including AMPK, mTOR and FATP1.
Conclusions: DEX-induced intramuscular lipid accumulation was aggravated by SFA but alleviated by unsaturated fatty
acid. The suppressed AMPK and augmented mTOR signaling pathways were involved in glucocortcoid-mediated enhanced
intramuscular fat accumulation.
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Introduction
Fatty acids and glucose are the primary skeletal muscle fuels.
Excessive glucocorticoid (GC) has been correlated with a pre-
disposition to many metabolic syndromes, including dyslipide-
mia and insulin resistance [1]. GC has an important effect on
lipid metabolism in muscles. GC and insulin act together to
promote intramyocellular lipid accumulation in mammals [2]
and chickens [3]. Compared with mammals, birds have higher
level of glucose and lower concentration of insulin [4,5], and
have more refractory insulin cascade in skeletal muscle tissues
[4,6]. Increased blood lipid flux and mismatched lipid uptake
and oxidation are suggested to be responsible for intramyocel-
lular lipid accumulation in chickens [3,7,8]. The study on
chicken model would be helpful to the understanding of
intramyocellular lipid accumulation.
The type of fatty acid likely affects mitochondrial utilization.
Myotube mitochondrial activity is increased with unsaturated fatty
acid (UFA, [9]) but is impaired by SFA [9,10]. Whether
imbalanced fatty acid uptake and utilization induced by GC is
influenced by different types of fatty acids remains unclear.
In mammals, AMP-activated protein kinase (AMPK) is involved
in cellular energy homeostasis regulation. AMPK, which is
thought to be a positive regulator of intracellular fatty acid
metabolism, is activated by an increase in the AMP to ATP ratio
[11]. AMPK phosphorylates and inactivates acetyl-CoA carbox-
ylase (ACC) and, in turn, diminishes malonyl-CoA; thus, carnitine
palmitoyl transferase 1 (CPT1) inhibition is relieved, and free fatty
acid entry into the mitochondria is facilitated for b-oxidation [12].
Therefore, excessive lipid accumulation in the skeletal muscle in
obesity could be from the dysregulation of the AMPK/malonyl-
CoA fuel-sensing system [13]. AMPK activation stimulates fatty
acid oxidation in the skeletal muscle by activating PPARs [14].
The functional liver kinase B1 (LKB1)/AMPK pathway in
chickens is similar to the pathway in mammals [15].
Mammalian target of rapamycin (mTOR) is a serine/threonine
protein kinase that has been proposed to play a central role in
skeletal muscle nutrient and energy sensing, by phosphorylating
two downstream proteins, eukaryotic initiation factor 4E-binding
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Porstmann et al. [17] demonstrated that the expression of enzymes
involved in lipid biosynthesis, such as ACC, was regulated by the
Akt/mTOR signaling network. Furthermore, mTOR inhibition in
rat skeletal muscle cells improved fatty acid oxidation [18].
Excessive lipid availability and AMPK are involved in mTOR
regulation. Lipid-induced mTOR activation and insulin resistance
in rat skeletal muscle were reversed by improved muscle AMPK
activation [19]. In mammalian skeletal muscle cells, GC could
abrogate mTOR signaling by dephosphorylating p70S6K and 4E-
BP1 [20]. Therefore, we hypothesize that the different fatty acid
types treatment (FA) may affect the GC induction of intramuscular
lipid accumulation, which involves the AMPK and mTOR
signaling pathways.
Herein, fast growing broiler chickens with high muscle yield and
feed efficiency were used as a model for muscle development [21].
Two types of skeletal muscle tissues, oxidative and glycolytic
muscles, were investigated to determine tissue specificity in the
regulation of lipid metabolism. Dexamethasone (DEX), a synthetic
GC that is specific for the GC receptor and delayed plasma
clearance [22], was employed to induce the hyperglucocorticoid
milieu [3]. Our results indicate that DEX-stimulated lipid
deposition was augmented by SFA, but alleviated by UFA. The
suppressed AMPK and augmented mTOR signaling pathways
were involved in GC-mediated enhanced intramuscular fat
accumulation. These findings allow a better view on the metabolic
perturbations associated with long-term GC use and dietetical
therapy in clinical setting, in a different biological system.
Materials and Methods
Ethics Statement
All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee of Shandong
Agricultural University (No. 2001002, Figure S1) and performed
in accordance with the ‘‘Guidelines for Experimental Animals’’ of
the Ministry of Science and Technology (Beijing, China). All
surgery was performed according to Recommendations proposed
by European Commission (1997), and all efforts were made to
minimize suffering.
Birds and Husbandry
Male broiler chicks (Arbor Acres, Gallus gallus domesticus) were
obtained from a local hatchery at 1 d of age and were reared in
an environmentally controlled room. The brooding temperature
was maintained at 35uC (65% RH) for the first 2 days, then
decreased gradually to 21uC (45% RH) until day 28 and was,
thereafter, maintained through the end of the experiment (day
38). The light regime was 23L: 1D. All chickens received a starter
diet with 21.5% crude protein and 12.37 MJ/kg of metabolisable
energy until day 21, after which they received a grower diet with
19.5% crude protein and 12.90 MJ/kg of metabolisable energy
[23]. All birds had free access to feed and water during the
rearing period.
Treatment
At 31 d of age, 144 broilers with similar body mass (BM) were
allocated to 9 groups, and each group had 16 chickens. The
chickens were randomly subjected to one of the following 3
treatments for 7 days: oral infusion of palmitic acid (51.3 mg/kg
BM, PA), oleic acid (56.5 mg/kg BM, OA) dissolved with
Tween80, and sham infusion of a vehicle-Tween80 (PLA). At 35
d of age, half of the chickens from each group were either
randomly exposed to subcutaneous injection of DEX (2 mg/kg
BM per day, DEX, [3]) twice per day or sham treated with
vehicle-saline (NORM) for 3 days. The use of Tween80 has been
validated in previous experiments with regard to lipid metabolism
[24,25]. BM and feed intake were recorded daily.
At 38 d of age, 4 chickens with similar BM (14366353 g) were
selected from each pen. After a 12-h feed withdrawal, a blood
sample was drawn from a wing vein using a heparinized syringe
within 30 s and collected in iced tubes. Plasma was obtained after
centrifugation at 400 g for 10 min at 4uC and was stored at
220uC for further analysis. Immediately after the blood sample
was obtained, chickens were killed by cervical dislocation,
following exsanguination [26], and then the liver, abdominal fat,
subcutaneous fat in the cervical and thigh regions and breast and
thigh muscle were harvested and weighed. A 1 to 2 g muscle tissue
sample was, respectively, obtained from the left PM (M. pectoralis
major, fast-twitch glycolytic fiber type muscle) and BF (M. biceps
femoris, slow-twitch oxidative fiber type muscle), cooled down in
liquid nitrogen and stored at 270uC for further analysis.
Plasma Parameters
The concentrations of glucose (No. F006) and TG (No. F001) in
plasma were measured spectrophotometrically using commercial
diagnostic kits (Jiancheng, Nanjing, China). The concentration of
VLDL was determined using the method described by Griffin and
Whitehead [27].
The insulin in plasma was measured using a radioimmunoassay
with guinea pig anti-porcine insulin serum (3V, Weifang, China).
In this measurement,
125I-labeled porcine insulin competes with
chicken insulin for sites on an insulin-porcine antibody that is
immobilized to the wall of a polypropylene tube. A large cross-
reaction has been observed between chicken insulin and the
guinea pig anti-porcine sera [28]. The insulin herein is referred to
as immunoreactive insulin.
Intramyocellular Lipid Accumulation
The accumulation of cytoplasmic lipid droplets was visualized
by Oil Red O staining according to Lillie and Fullmer [29].
Briefly, frozen tissues were cut in a Leica CM-1850 cryostat
microtome (Leica, Wetzlar, Germany). Sixteen- micrometer-thick
sections were fixed in formaldehyde and stained with filtered 0.5%
Oil Red O (Sigma-Aldrich, St Louis, MO, USA). Morphometric
analysis was performed on 10 fields containing transverse muscle
fiber sections that were chosen at random for each chicken’s
muscles and photographed under an Olympus CX-41 phase-
contrast microscope (Olympus, Tokyo, Japan). The volume
density of each Oil Red O positive fiber within the muscle tissue
was determined by Weibel’s point-counting method [30].
ATP and AMP Content
The concentrations of ATP and AMP in skeletal muscle tissue
were measured with a Waters 515 reversed-phase high perfor-
mance liquid chromatography system (Waters, Milford, MA,
USA) using a modification of the approach described by Ryder
[31] and Smolenski and Yacoub [32]. Separation was performed
with a reversed-phase Diamonsil C18 column (250 mm64.6 mm,
Dikma, Beijing, China) that was equilibrated with methyl alcohol
at room temperature. The injection volume was 10 mL, and flow
was maintained at 1 mL/min. Detection of ATP and AMP was
achieved at 254 nm with a Waters 2487 Dual l Absorbance
Detector (Waters, Milford, MA, USA) at room temperature. The
results were quantitated with external standards (Sigma-Aldrich,
St Louis, MO, USA).
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AMPK activity was measured by detecting
32P release from
[
32P]ATP(5mCi/assay) and with SAMS peptide (His-Met-Arg-Ser-
Ala-Met-Ser-Gly-Leu- His-Leu-Val-Lys-Arg-Arg) as the ACC
target analog as previous described [33,34]. The incorporated
radioactivity was measured in a SN-6930 scintillation counter
(Rihuan, Shanghai, China). The protein concentration was
determined using a protein assay kit (Jiancheng, Nanjing, China).
CPT1 activity was defined as 1nmol of CoA-SH released from
1mg of muscle tissue protein per minute according to the method
described by Bieber et al. [35]. Protein concentration was
determined using a protein assay kit (Jiancheng, Nanjing, China).
RNA Preparation and Analysis
Gene expression was measured using real-time RT-PCR.
Briefly, total RNA from PM and BF was extracted using TRIzol
(Invitrogen, San Diego, CA, USA). The quantity and quality of the
isolated RNA were determined using a biophotometer (Eppendorf,
Hamburg, Germany) and by agarose-gel electrophoresis, re-
spectively. Next, reverse transcription was performed using a RT
reaction (10 mL) that consisted of 500 ng total RNA, 5 mmol/L
MgCl2,1 mL RT buffer, 1 mmol/L dNTP, 2.5 U AMV,
0.7 nmol/L oligo d(T), and 10 U Ribonuclease inhibitor (Ta-
KaRa, Dalian, China). cDNA was amplified in a 20 mL PCR
reaction containing 0.2 mmol/L of each specific primer (Sangon,
Shanghai, China) and SYBR green master mix (TaKaRa, Dalian,
China). Real-time PCR was performed at 95uC for 10 s of
predenaturation, followed by 40 cycles, and each cycle consisted of
denaturation at 95uC for 5 s and annealing and extension at 60uC
for 40 s. Primers against GAPDH and 18S ribosomal RNA (18S
rRNA) were amplified and used as internal controls to normalize
the differences in individual samples. The primer sequences for
chicken are listed in Table 1. The PCR products were verified by
electrophoresis on a 0.8% agarose gel and DNA sequencing.
Standard curves were generated using pooled cDNA from the
samples that were assayed, and the comparative CT method
(2
2DDCT) was used to quantitate mRNA expression in accordance
with Livak and Schmittgen [36]. All of the samples were run in
duplicate, and the primers were designed to span an intron to
avoid genomic DNA contamination.
Protein Preparation and Western Blot
Proteins were extracted from chicken PM and BF. Muscle
samples were homogenized on ice in radioimmunoprecipitation
assay buffer (50 mmol/L Tris-HCl at pH 7.4, 1% NP-40, 0.25%
sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA,
1 mmol/L phenylmethylsulfonyl fluoride, 1 mg/mL aprotinin,
1 mg/mL leupeptin, 1 mg/mL pepstatin, 1 mmol/L sodium
orthovanadate, 1 mmol/L sodium fluoride) and centrifuged at
12 000g for 5 minutes at 4uC. Protein concentration was
determined using the BCA assay kit (Beyotime, Jiangsu, China).
Samples were boiled at 100uC for 5 minutes in 56sample buffer.
Protein extracts (80 mg) were electrophoresed in 7.5–10% SDS
polyacrylamide gels (Bio-Rad) according to the Laemmli method
[37]. Separated proteins were then transferred onto a nitrocellulose
membrane in Tris-glycine buffer containing 20% methanol.
Membranes were blocked and immunoblotted with a 1:1000
dilution of the following primary antibodies: P-AMPKa (Thr172)
antibody, AMPKa antibody, P-mTOR (Ser2448) antibody,
mTOR antibody, P-p70S6K (Thr389) antibody, and p70S6K
antibody. The antibodies were purchased from Cell Signaling
Technology (Beverly, MA, USA) and were previously validated for
use with chicken samples [15,38,39]. The P-Akt (Ser473) antibody
and Akt antibody were purchased from Beyotime (Jiangsu, China).
Protein was detected using either goat anti-rabbit IgG (H+L)-HRP
conjugated secondary antibody (1:2000, Bio-Rad, Richmond, CA)
or HRP-labeled goat anti-mouse IgG (H+L) secondary antibody
(1:1000, Beyotime, Jiangsu, China) with enhanced chemilumines-
cence (ECL) plus western blot detection reagents (Beyotime,
Jiangsu, China). b-actin was used as an internal control (Beyotime,
Jiangsu, China). Western blots were quantified using the ImageJ
1.43 software (National Institutes of Health, Bethesda, MD) after
the films were scanned.
Statistical Analysis
A two-way ANOVA model was used to analyze the primary
effects of the DEX and FA treatments and their interaction using
Statistical Analysis Systems statistical software package (Version
8e, SAS Institute, Cary, NC, USA). Homogeneity of variances
among groups was confirmed using Bartlett’s test (SAS Institute).
When the primary effect of a treatment was significant, the
Table 1. Gene-specific primer of related genes.
Gene Genebank number Primers sequences (59R39) Product size
FATP1 DQ352834 Forward tcaggagatgtgttggtgatggat 138 bp
Reverse cgtctggttgaggatgtgactc
GAPDH NM_204305 Forward ctacacacggacacttcaag 244 bp
Reverse acaaacatgggggcatcag
INSR AF111857 Forward caaacggtgaccaagcctca 186 bp
Reverse catcctgcccatcaaactccg
L-CPT1 AY675193 Forward ggagaacccaagtgaaagtaatgaa 135 bp
Reverse gaaacgacataaaggcagaacaga
M-CPT1 DQ314726 Forward gatttctgctgcttccaattcg 92 bp
Reverse tgcagcgcgatctgaatg
PPARa AF163809 Forward agacaccctttcaccagcatcc 167 bp
Reverse aacccttacaaccttcacaagca
18SrRNA AF173612 Forward ataacgaacgagactctggca 136 bp
Reverse cggacatctaagggcatcaca
doi:10.1371/journal.pone.0036663.t001
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multiple range analysis. The mean was considered to be
significantly different at P,0.05.
Results
Animal Growth and Tissue Development
DEX significantly decreased BM gain (P,0.0001), whereas FA
action was interacted by DEX treatment (P,0.01), and the
NORM-OA chickens had the highest BM gain. OA increased BM
gain in NORM-chickens. After DEX treatment, however, FA had
no significant effect on BM gain (Table 2). DEX had no significant
effect on feed intake. However, FA tended to have an effect on
feed intake (P=0.07). Feed efficiency was significantly decreased
by DEX (P,0.0001) and not by FA. There was no significant
interaction between DEX and FA for either feed intake or feed
efficiency (Table 2).
The liver weight was significantly influenced by DEX, FA, and
their interaction (P,0.0001, Table 3). The DEX-PA chickens had
the highest and Control chickens had the lowest. DEX signifi-
cantly improved the abdominal (P,0.0001), cervical (P,0.01),
and thigh fat masses (P,0.0001). In contrast, FA treatment
affected significantly only in abdominal fat (P,0.01). PA chickens
had higher abdominal fat mass compared with either the OA or
PLA groups. DEX and FA had no significant interaction in
abdominal, cervical, and thigh fat masses. Neither DEX nor FA
treatment had a detectable effect on breast and thigh muscle
masses (Table 3).
Intramuscular Lipid Accumulation
The intramuscular fat (IMF) content in PM was significantly
affected by DEX (P,0.0001), FA (P,0.0001), and their in-
teraction (P,0.05, Figure 1). The DEX-PA chickens had the
highest and Control chickens had the lowest. After DEX
treatment, PA chickens had the highest IMF content, and the
OA group had the lowest IMF level. In NORM-chickens, the IMF
content was higher in PA chickens than the IMF content in either
the OA or PLA group, whereas there was no significant difference
between OA and PLA treated chickens.
In BF, the IMF content was significantly affected by DEX, FA,
and their interaction (P,0.0001, Figure 2). The DEX-PA chickens
had the highest and Control chickens had the lowest. In the DEX
treated chickens, the PA chickens had higher and the OA chickens
had lower IMF level compared with the DEX-PLA chickens. In
the NORM treated chickens, however, the PA group had higher
IMF level, while PLA chickens had lower IMF level compared
with OA chickens.
Plasma Parameters
Plasma concentrations of glucose, insulin, TG, and VLDL were
significantly increased by DEX (P,0.05, Figure 3). FA had
a significant effect on plasma glucose (P,0.05), insulin (P,0.05),
TG (P,0.05), and VLDL (P,0.0001). PA chickens had higher
levels of glucose, insulin, and VLDL than those in the OA and
PLA groups, and TG concentration was increased after PA and
OA infusion compared with PLA treatment. DEX and FA
interacted for VLDL (P,0.001) but not for glucose, insulin, and
TG. For the DEX treated chickens, the stimulating effect of DEX
on VLDL concentration was enhanced by PA and alleviated by
OA infusion.
Enzyme Activity
In PM, neither DEX nor FA significantly affected the AMP to
ATP ratio (P,0.05, Figure 4A). However, there was a significant
interaction between DEX and FA treatments (P,0.05), and the
DEX-PA chickens had a lower AMP to ATP ratio than the PA
Table 2. The effect of DEX (daily subcutaneous injection of
2 mg/kg BM for 3d) and FA treatments (daily gastric infusion
of palmitic acid or oleic acid for 7d) on the growing
performance of broiler chickens.
Item Treat DEX NORM Probability
BM gain (g/d) PA 28.260.86 c 42.260.27 b PDEX,0.0001
OA 26.561.32 c 51.060.99 a PFA=0.11
PLA 31.261.86 c 41.562.85 b PDEX6FA=0.0022
Feed intake (g/d) PA 99.063.84 ab 92.466.10 b PDEX=0.38
OA 93.263.52 ab 95.863.21 ab PFA=0.07
PLA 10763.60 a 10264.02 ab PDEX6FA=0.51
Feed:gain (g/g) PA 3.5160.03 a 2.1960.14 bc PDEX,0.0001
OA 3.5260.09 a 1.8860.10 c PFA=0.30
PLA 3.4560.22 a 2.4960.28 b PDEX6FA=0.17
Values are means 6 SE (n=3);
a, b, c: Means within the same item with different letter differ significantly,
P,0.05.
PDEX: P-value of main effect of DEX treatment; PFA: P-value of main effect of FA
treatment; PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.t002
Table 3. The effect of DEX (daily subcutaneous injection of
2 mg/kg BM for 3d) and FA treatments (daily gastric infusion
of palmitic acid or oleic acid for 7d) on the yield of skeletal
muscle and liver and the fat accumulation in adipose tissues
(% BM) of broiler chickens.
Item Treat DEX NORM Probability
Liver PA 4.0860.10 a 2.0860.04 c PDEX,0.0001
OA 2.8460.03 b 2.0160.04 c PFA,0.0001
PLA 3.0360.16 b 1.9660.07 c PDEX6FA,0.0001
Abdominal fat PA 1.5660.12 a 1.1160.15 b PDEX,0.0001
OA 1.2460.11 ab 0.66160.09 c PFA=0.0017
PLA 1.4160.10 ab 0.55860.09 c PDEX6FA=0.21
Cervical fat PA 0.34860.05 ab 0.17560.03 b PDEX=0.0049
OA 0.35360.05 ab 0.25760.05 ab PFA=0.70
PLA 0.37760.09 a 0.23060.07 ab PDEX6FA=0.80
Thigh fat PA 0.36660.03 ab 0.17060.03 d PDEX,0.0001
OA 0.32260.03 bc 0.16160.03 d PFA=0.11
PLA 0.49160.10 a 0.19660.05 cd PDEX6FA=0.37
Breast PA 17.160.52 17.160.50 PDEX=0.99
OA 17.660.36 17.160.30 PFA=0.87
PLA 17.060.59 17.460.42 PDEX6FA=0.59
Thigh PA 13.660.26 13.560.37 PDEX=0.28
OA 13.860.29 13.660.30 PFA=0.81
PLA 13.960.27 13.660.26 PDEX6FA=0.96
Values are means 6 SE (n=12);
a, b, c, d: Means within the same item with different superscript differ
significantly, P,0.05.
PDEX: P-value of main effect of DEX treatment; PFA: P-value of main effect of FA
treatment, PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.t003
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effect on the AMP to ATP ratio in BF (P,0.001). DEX treated
chickens had a significantly lower AMP to ATP ratio than NORM
chickens. Compared with the PLA group, the AMP to ATP ratio
was decreased after PA and OA treatment.
The AMPK activity was significantly suppressed by DEX in
both PM and BF tissues (P,0.01, Figure 4B). FA treatment,
however, had no significant influence on AMPK activity in either
PM or BF and no significant interaction. CPT1 activity was
suppressed by DEX treatment in PM (P,0.05) and BF muscle
(P,0.001, Figure 4C). In contrast, FA treatment affected
significantly only in BF, and CPT1 activity was decreased by PA
infusion (P,0.05).
Gene mRNA Expression
DEX treatment significantly upregulated the gene expression of
fatty acid transport protein 1 (FATP1) in PM (P,0.01) and in BF
(P,0.0001, Figure 5A). In contrast, the FATP1 mRNA level was
significantly increased by PA in PM (P,0.0001) and decreased by
OA in BF (P,0.05), compared with PLA-treated chickens. DEX
and FA interacted significantly in BF (P,0.05), and the effect from
DEX was suppressed by OA infusion.
DEX treatment significantly downregulated the expression level
of liver-carnitine palmitoyl transferase 1 (L-CPT1) in PM
(P,0.01), whereas the converse was true in BF (P,0.05,
Figure 5B). In contrast, muscle-carnitine palmitoyl transferase 1
(M-CPT1) expression differed between DEX and NORM only in
BF (P,0.01) and not in PM (Figure 5C). The mRNA levels for L-
CPT1 and M-CPT1 in PM were significantly decreased by PA,
whereas OA infusion significantly upregulated the expression of L-
CPT1 (P,0.0001). In BF, however, L-CPT1 and M-CPT1
expressions were significantly downregulated by either PA or
OA (P,0.05).
DEX treatment had no significant influence on insulin receptor
(INSR) gene expression in PM, but the converse was true for BF
(P,0.0001, Figure 5D). In contrast, FA treatment had a significant
effect on PM (P,0.0001) but not BF. The INSR mRNA level was
significantly upregulated by OA infusion compared with the PA
and PLA groups in PM.
PPARa gene expression was significantly upregulated by DEX
in BF (P,0.05) but not in PM (Figure 5E). FA treatment
significantly influenced the PPARa mRNA level in PM
(P,0.0001) and BF (P,0.05). The PPARa expression level was
upregulated by OA in PM but was downregulated by OA in BF.
Protein Phosphorylation
As an internal control, b-actin protein abundance was not
significantly affected by either DEX, FA, or an interaction
between treatments in either PM or BF (Figure 6E).
The abundance of the P-AMPKa protein at Thr172 was
significantly decreased by DEX in PM and BF (P,0.0001,
Figure 6A). In contrast, a significant effect from FA treatment was
detected in BF (P,0.001) but not PM. In BF, PA decreased the P-
AMPKa level compared with either the OA or PLA group. DEX
and FA treatments interacted in PM (P,0.05). In the DEX treated
chickens, the OA chickens had higher P-AMPKa level compared
with the DEX-PLA chickens.
The phosphorylation level of Akt at Ser473 was not affected by
either DEX or FA treatment (Figure 6B). DEX treatment
significantly suppressed the phosphorylation level of mTOR at
Ser2448 in PM (P,0.05) and BF (P,0.001, Figure 6C). A
significant effect from FA treatment was detected only in BF, and
the phosphorylation of mTOR was higher after PA and OA
treatments than in the PLA group (P,0.01). In PM, neither DEX
nor FA treatment had a significant effect on the phosphorylation
level of p70S6K at Thr389 (Figure 6D). In contrast, in BF, DEX
treatment increased the level of P-p70S6K (P,0.05). Compared
with the PLA group, PA or OA infusion significantly upregulated
the level of phosphorylated p70S6K (P,0.0001). DEX and FA
treatments interacted in BF (P,0.0001). After DEX treatment, the
PA chickens had higher P-p70S6K level compared with the DEX-
PLA chickens.
Discussion
We firstly demonstrated the interaction between GC and FA
treatments on IMF accumulation in broiler chickens. The present
study shows that exogenous GC administration and dietary PA
infusion augmented the IMF content in skeletal muscle tissues by
improving fatty acid uptake and suppressing fatty acid oxidation.
DEX-enhanced IMF accumulation was aggravated by SFA (PA)
but alleviated by UFA (OA) infusion. The result suggests that
suppressed AMPK and augmented mTOR signaling pathways
may be involved in enhanced IMF accumulation by GC.
DEX Facilitates IMF Accumulation
In previous studies, GC administration increased hepatic
lipogenesis and fat accumulation in adipose tissues in rats [40]
and chickens [41]. Consistent with previous results, DEX
treatment retarded BM gain, increased liver weight, and
abdominal fat in chickens, which suggests an altered energy
redistribution toward lipid deposition. Likewise, enhanced IMF
accumulation by DEX exposure was consistent with previous
result in rats [42] and suggested that GC augmented IMF in
chickens. Moreover, DEX increased IMF content in PM and BF,
indicating that DEX has an effect regardless of muscle types.
Lipid accumulation in skeletal muscle cells primarily depends on
the net balance between fatty acid uptake and utilization. In this
process, the genes related to fatty acid transport and oxidation,
such as FATP1 and CPT1, are involved [3]. In DEX-treated
chickens, FATP1 overexpression in PM (1.70 fold of NORM) and
BF (8.96 fold of NORM) suggests an increased fatty acid uptake
capacity in skeletal muscles, especially in BF, and the increased
plasma TG and VLDL concentrations indicate an augmented
circulating lipid flux. Moreover, the insulin-stimulated lipid uptake
by skeletal muscle was reduced in FATP1-null rats [43],
demonstrating that insulin can regulate fatty acid uptake via
FATP1 activation, and INSR expression herein was upregulated
in response to the increased circulating insulin. These results
suggest that DEX treatment improves fatty acid uptake in skeletal
muscles.
In rats, it was speculated that the relative increase in IMF after
DEX treatment resulted from a decrease in lipid oxidation [42],
and the suppression in conversion of inactive to active cortisol
Figure 1. Oil Red O staining of skeletal muscle for cytoplasmic lipid droplets in PM. Figure A–F show the effect of DEX (daily subcutaneous
injection of 2 mg/kg body mass for 3d) and FA treatments (daily gastric infusion of either palmitic acid or oleic acid for 7d) and the interaction
between DEX and FA on lipid accumulation in the myocytes from PM in broiler chickens. Figure G indicates the volume density (Vv6100) of Oil
Red O-positive muscle fibers in skeletal muscle. The values are the means 6 SE (n=8); Means with a different letter differ significantly (P,0.05). PDEX:
P-value of main effect of DEX treatment; PFA: P-value of main effect of FA treatment; PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.g001
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36663Figure 2. Oil Red O staining of skeletal muscle for cytoplasmic lipid droplets in BF. Figure A–F show the effect of DEX (daily subcutaneous
injection of 2 mg/kg body mass for 3d) and FA treatments (daily gastric infusion of either palmitic acid or oleic acid for 7d) and the interaction
between DEX and FA on lipid accumulation in myocytes from BF in broiler chickens. Figure G indicates the volume density (Vv6100) of Oil Red O-
positive muscle fibers in skeletal muscle. The values are the means 6 SE (n=8); Means with a different letter differ significantly (P,0.05). PDEX: P-value
of main effect of DEX treatment; PFA: P-value of main effect of FA treatment; PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.g002
Figure 3. The effect of DEX and FA on plasma parameters. Figure A, B show the effect of DEX (daily subcutaneous injection of 2 mg/kg body
mass for 3d) and FA treatments (daily gastric infusion of either palmitic acid or oleic acid for 7d) and the interaction between DEX and FA on the
plasma concentration of glucose (mmol/L, A), insulin (mIU/Ml, A), TG (mmol/L, B), and VLDL (Abs, B) in broiler chickens. The values are the means 6 SE
(n=12); Means with a different letter differ significantly (P,0.05). PDEX: P-value of main effect of DEX treatment; PFA: P-value of main effect of FA
treatment; PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.g003
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these reports, herein, the decreased CPT1 activity by DEX in both
muscles indicates suppressed lipid oxidation. Moreover, the
transcription of L-CPT1, but not M-CPT1, was attenuated in
PM, while L-CPT1 and M-CPT1 expression were upregulated in
BF, which indicates that the effect of DEX on the regulation of
CPT1 is muscle-type dependent.
Collectively, the results suggest that excessive GC triggers IMF
accumulation, primarily through the facilitated fatty acid uptake
and retarded fatty acid oxidation in either glycolytic or oxidative
muscle.
AMPK Inhibition and mTOR Activation are Involved in
DEX-facilitated IMF Accumulation
It is thought that AMPK is an important regulator of
intracellular fatty acid metabolism. Phosphorylation at Thr172
in an a isoform by an upstream kinase is known to be required for
AMPK activity [45]. In rats, acute DEX administration promoted
ACC phosphorylation and increased cardiac PA oxidation, likely
by activating AMPK [46], and chronic GC treatment inhibited
AMPK activity in adipose tissue and heart, while stimulating it in
the liver and hypothalamus [47]. Recently, it was reported that
transcriptomic analysis of the liver suggested marked overlap
between the AMPK and GC signaling pathways that was
primarily directed by AMPK to GC action through an AMPK-
mediated energy control system that modulates GC action at
target tissues [48]. In the chicken herein, the lower AMP to ATP
ratio coincided with decreased AMPK activity and AMPKa
phosphorylation in BF, and the decreased CPT1 activity was
consistent with the observation that the AMPK activity and
phosphorylation were suppressed, which suggests that the AMPK
signaling pathway is involved in the suppressed fatty acid oxidation
in DEX-treated chickens. In a rat model, AMPK activity in
response to muscle electrical stimulation was reduced after a 2-wk
treatment of GC, and this response is believed to be involved in
insulin resistance and adiposity [49]. This result suggests that the
AMPK pathway is suppressed by long-term DEX administration,
which is likely responsible, at least partially, for the augmented
IMF accumulation.
Figure 4. The effect of DEX and FA on AMPK/CPT signal pathway. Figure A–C show the effect of DEX (daily subcutaneous injection of 2 mg/
kg body mass for 3d) and FA treatments (daily gastric infusion of either palmitic acid or oleic acid for 7d) and the interaction between DEX and FA
on AMP to ATP ratio (A), AMPK activity (B) and CPT1 activity (C) in PM and BF of broiler chickens. The values are the means 6 SE (n=8); Means with
a different letter differ significantly (P,0.05). PDEX: P-value of main effect of DEX treatment; PFA: P-value of main effect of FA treatment; PDEX6FA:P -
value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.g004
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mTOR signaling with lipid metabolism. Um et al. [50] reported
that S6K1-deficient mice exhibited an elevated CPT1 mRNA
expression and an enhanced fatty acid oxidation capacity in
skeletal muscle. Sipula et al. [18] reported that physiological
mTOR inhibition promoted b-oxidation, at least in part, as
a direct result of CPT activity increase, indicating a role for
mTOR downregulation in lipid utilization. Acute DEX treatment
Figure 5. The effect of DEX and FA on lipid-related gene mRNA expression. Figure A2E show the effect of DEX (daily subcutaneous
injection of 2 mg/kg body mass for 3d) and FA treatments (daily gastric infusion of either palmitic acid or oleic acid for 7d) and the interaction
between DEX and FA on the mRNA expression of FATP1 (A), L-CPT1 (B), M-CPT1 (C), INSR (D), and PPARa (E) in PM and BF of broiler chickens. The
values are the means 6 SE (n=6); Means with a different letter differ significantly (P,0.05). PDEX: P-value of main effect of DEX treatment; PFA: P-value
of main effect of FA treatment; PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.g005
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treatment abrogated the stimulatory effect of amino acid infusion
on the phosphorylation of 4E-BP1, without affecting p70S6K [51].
In the present study, DEX upregulated the P-mTOR level in both
muscles as well as the P-p70S6K level in BF, indicating that DEX
treatment activated the mTOR pathway. The result suggests that
the mTOR signaling pathway may be involved in GC regulation
of muscle lipid metabolism. These novel observations in chickens
Figure 6. The effect of DEX and FA on lipid-related gene protein expression. Figure A2E show the effect of DEX (daily subcutaneous
injection of 2 mg/kg body mass for 3d) and FA treatments (daily gastric infusion of either palmitic acid or oleic acid for 7d) and the interaction
between DEX and FA on the protein phosphorylation of AMPKa (A), Akt (B), mTOR (C), and p70S6K (D), as well as the b-actin protein level (E) in PM
and BF of broiler chickens. The values are the means 6 SE (n=4); Means with a different letter differ significantly (P,0.05). PDEX: P-value of main effect
of DEX treatment; PFA: P-value of main effect of FA treatment; PDEX6FA: P-value of interaction between DEX and FA treatments.
doi:10.1371/journal.pone.0036663.g006
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[18] in mammals, who reported that mTOR inhibition was shown
to elevate CPT1 mRNA expression and enhance muscle fatty acid
oxidation. Phosphorylation of mTOR Ser2448, which positively
correlated with mTOR activity [52], was inhibited by AMPK
activation [53]. As upstream physiological counter-regulators of
mTOR, lipid-induced mTOR activation and insulin resistance
were restored to normal by activated AMPK in both in vivo rat
skeletal muscle [19] and hepatocytes [54]. The crosstalk among
the GC, AMPK, and mTOR signaling pathways must be
investigated further.
Insulin and downstream signaling proteins, such as phosphati-
dylinositol-3-kinase (PI3K) and Akt, play an important role in
glucose and lipid metabolism. Although there is an apparent
insulin insensitivity in chicken muscle, GC may impair insulin
signaling in chicken muscle to some extent [55], through
competing with insulin receptor substrate 1 for association of
PI3K [56]. In this study, DEX administration resulted in insulin
resistance, as indicated by hyperglycemia and hyperinsulinemia,
which is consistent with previous results in mammals [57] and
chickens [23]. Akt expression was not affected by DEX treatment,
even with hyperinsulinemia and upregulated INSR, indicating the
unaltered insulin signaling cascade. In chickens, however, the early
steps of the insulin signaling pathway differ from those of
mammals, basal levels of tyrosine phosphorylation of INSR and
of PI3K activity are much higher in chickens than in rats [4].
Contrasting with the strong activation of all components of the
cascade by insulin in rats, none was observed in chicken muscles
[4,55]. GC impairs insulin signaling in response to re-feeding to
some extent in chicken muscle (55), and the present result
demonstrates that GC does not impair the insulin signaling
pathway at basal state. In chickens, the Akt/TOR/p70S6K
pathway is activated by re-feeding and insulin injection [58]. The
activated mTOR signals in DEX-treated chickens in this study
imply that DEX can induce the mTOR signaling pathway via
other pathways. The role of Akt in GC-mediated lipid metabolism
needs a further study in vitro.
In humans, skeletal muscle PPARa expression and genes
regulating lipid metabolism are tightly linked [59]. Consistent
with this result, the present results showed a similar trend in the
gene expression of M-CPT1 and PPARa in DEX-treated
chickens. PPARa activation increased fatty acid oxidation in
skeletal muscle [60], and AMPK activation increased skeletal
muscle lipid oxidation by activating PPARa [14]. Herein, the
PPARa expression was upregulated in BF and unaffected in PM,
suggesting that the change in the PPARa gene expression does not
play an important role in DEX-altered lipid metabolism.
Collectively, these results suggest that suppressed AMPK and
activated mTOR signals are involved in DEX-induced IMF
accumulation.
IMF Accumulation is Aggravated by PA Rather than OA
Although UFA and SFA can induce insulin resistance and
obesity, there is evidence to suggest that SFA is more effective than
UFA [61,62]. PA and OA are controlled differently by myotubes.
PA accumulates as diacylglycerol and triacylglycerol, whereas OA
accumulates as intracellular free fatty acid [63], which indicates
that the OA is preferable for oxidation. Moreover, SFA, but not
UFA, promoted ceramide accumulation, which is a common
molecular intermediate linking several different pathological
metabolic stresses to the induction of insulin resistance [64]. In
accordance with previous results in mammals, the IMF content
augmented by PA, not OA, indicates that PA facilitates IMF
accumulation in chickens. Coinciding with increased IMF content
from PA treatment, blood glucose and lipid flux were increased in
PA-treated chickens (glucose, +6.06%; VLDL, +14.9%) but the
change was less obvious from OA infusion (glucose, 21.23%;
VLDL, +10.6%).
The upregulated FATP1 gene expression in PM, downregulated
L- and M-CPT1 gene expression and suppressed CPT1 activity by
PA infusion in PM and BF indicate that PA infusion induces lipid
accumulation and suppresses lipid oxidation. In contrast, the
decreased FATP1 expression and unaffected CPT1 activity in BF
from OA treatment should be responsible, at least partially, for the
unaffected IMF content.
Hickson-Bick et al. [65] reported that AMPK was activated in
cultured rat cardiomyocytes by PA and OA treatment. AMPKa
Thr172 was also phosphorylated in rat hearts infused with SFA
without changes to cellular energy charge [66]. Further, SFA and
UFA increased AMPK activity independent of changes in cellular
AMP content in L6 myoblasts [67]. These results imply that
increased fatty acid availability may promote AMPK activation,
independent of the cellular AMP level. Herein, AMPK activity
was not significantly affected by FA treatment in either muscles,
and AMPKa phosphorylation was decreased in BF by PA
infusion. This result suggests that AMPK activity may not play
a primary role in increased IMF accumulation after PA treatment.
Recent evidence demonstrates that muscle mTOR is over-
activated in obese rodents, high-fat-fed rodents and in vitro L6
myotubes exposed to PA [19,68,69], and S6K1-null mice are
protected from high fat diet-induced adverse effects [50]. In
accordance with the studies in rodents, increased mTOR and
p70S6K phosphorylation in BF indicates the activation of mTOR
signals by FA infusion in chicken oxidative skeletal muscles. In the
glycolytic muscle, however, mTOR and p70S6K phosphorylation
were unaffected by FA treatment, suggesting that the effect of FA
treatment on the mTOR signaling pathway is tissue specific.
One of the major sites for SFA-mediated adverse function is
INSR [70]. In contrast, OA improves insulin signaling and
protects against PA-induced insulin resistance in L6 myotubes
[71]. We also observed that OA upregulated INSR mRNA
expression in glycolytic muscle and did not significantly alter the
circulating glucose/insulin balance, which indicates enhanced
insulin sensitivity. Akt Ser473 phosphorylation was significantly
increased in L6 myotubes after PA incubation [19], in contrast, PA
treatment had no effects on INSR expression or Akt phosphor-
ylation in present result. The PA CoA ester formation is critical for
its adverse effect on insulin action in hepatocyte cell [70], thus the
in vivo effect of FA treatment on the insulin signaling must be
investigated further.
Recently, PPARa signaling was shown to be associated with the
regulation of optimal substrate selection and disposition in skeletal
muscle according to its metabolic requirement [72]. Staiger et al.
[9] reported that PA and OA regulated PPARs expression
differentially, which suggests that mitochondrial activity was
increased by UFA but suppressed by SFA. The result herein
indicates that the regulation of FA on PPARa expression is
dependent on muscle type.
DEX-enhanced IMF Accumulation is Aggravated by PA,
but Alleviated by OA
The stress response is interfered by a high-fat diet in rat model
[73]. The combination of social stress and high-fat diet in a mice
model altered energy portioning with increased body fat [74].
Excess GC aggravated the development of glucose intolerance in
rats fed a high-fat diet [75]. Recently, it was proved that GC and
SFA were linked by ceramide to the induction of insulin resistance
in rats [64]. Herein, consistent with the previous studies in
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treatments in chicken model. This finding could allow a novel view
on different biological systems. We found that the DEX-stimulated
IMF deposition and plasma VLDL concentration were aggravated
by PA but alleviated by OA, and several pathways including
AMPK and p70S6K may be involved. The OA infusion alleviated
the DEX-decreased AMPKa.phosphorylation in PM, and PA
treatment accelerated the stimulating effect of DEX on P-p70S6K
level in BF. Compared with UFA enriched diet, SFA stimulated
conversion of inactive to active GC in rats [76], which could
explain the different regulation of PA and OA on DEX action in
present study.
Given the function of FATP1 and CPT1 on fatty acid uptake
and oxidation respectively, we speculate that the interaction
between DEX and FA treatments on FATP1 and CPT1 may
contribute to the altered IMF accumulation. The results showed
that the stimulating effect of DEX on FATP1 expression was
suppressed by OA infusion. Moreover, the stimulating effect of
OA on L-CPT1 expression in PM was alleviated in the presence of
DEX (P=0.07), and the suppression effect of OA on M-CPT1 in
PM was not detected in DEX-treated chickens (P=0.06).
However, the change at the transcriptional level was not consistent
with the observations on CPT1 activity, which suggests that OA
interacts with DEX only at the mRNA level.
In conclusion, DEX facilitated intramyocellular lipid accumu-
lation by incompatible fatty acid uptake and utilization. DEX-
induced IMF deposition was aggravated by SFA but alleviated by
UFA. This result suggests that suppressed AMPK and augmented
mTOR signaling pathways are involved. The regulating pathways
associated with in vivo FA infusion must be investigated further.
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